ABSTRACT
Pyrazole and quinoxaline synthesis is gaining popularity due to its wide range of pharmacological qualities, including antiviral, antagonist, antibacterial, anticancer, anti-inflammatory, analgesic, anti-prostate cancer, herbicidal, acaricidal, and insecticidal effects. A novel and innovative heterocyclic biologically active compound, 3-[5-(hydroxy1methyl)-1-phenylpyrazol-3-yl]-2-[2, 4, 5-trimethoxybenzylidine] hydrazonyl-quinoxaline abbreviated as (TMPyrQu) is prepared by simple low-cost method. The chemical structure of the compound is assigned based on IR, 1H NMR, 13C NMR as well as elemental analysis. TMPyrQu showed potent antimicrobial activity: higher antibacterial activity against p. aeruginosa, E. coli, S. aureus, Streptomyces (inhibition zone (mm) 16, 14, 19, 18, 12), respectively, than the standard antibiotic ampicillin for bacteria with corresponding inhibition zone (mm) (12, 11, 9, 13).The antifungal activity of TMPyrQu is higher than ampicillin Fluconazole biocide (inhibition zone of 16 mm and 11 mm, respectively). It also demonstrated robust antiviral activity against the hepatitis B and good anticancer activity and cytotoxicity on the cell lines HepG-2 (liver carcinoma) and MCF-7 (breast carcinoma), with higher performance for breast cancer. The TMPyrQu molecule has the potential to be a powerful anticancer and immunosuppressive medication. TMPyrQu showed strong antioxidant activity that represented a first-line defense against free radical and reactive oxygen species (ROS), that target lipids, protein, and nucleic acid contributing to the progression of many chronic diseases. The novelty of this study is that it is the first time a multidisciplinary biologically active compound has been synthesized and evaluates its biological activity as well as its effectiveness against breast and liver tumor from a chemical, biochemical and medicinal perspective. The lack of adequate evaluation of such promising biocompatible biologically active compounds, despite the fact that the COVID-19 virus affects the entire world is the driving factor behind this work.
ABSTRACT
A simple low-cost one-pot photodeposition synthesis with no hazardous reactants or products is used to make silver nanoparticles-activated carbon composite (SNPs@AC). The SNPs are homogenously and photodeposited and absorbed into the activated carbon matrix. Both SNPs and SNPs@AC composite have particle sizes around 10 nm and 100 nm, respectively. The SNPs@AC composite showed good antiviral activity to VERO (ATCC ccl-81) cells. Zeta potential of SNPs@AC composite is −25 mV, showing that this colloidal system is electrically stable and resistant to coagulation. For many Gram-positive and Gram-negative bacteria, the SNPs@AC composite demonstrated strong antibacterial efficacy. The SNPs@AC composite has 75.72 percent anti-inflammatory effect at concentration 500 µg/mL. This composite has a maximum non-toxic concentration (MNTC) of 78.125 g/mL, which corresponds to antiviral activity of up to 96.7 percent against hepatitis A. virus (HAV). It is suggested as a candidate for pharmaceutical formulations, such as integration into the manufacture of N95 masks for COVID-19 infection protection. Concentration 160 μg/mL SNPs@AC composite has antioxidant activity 42.74% percent. The SNPs@AC composite exhibited selective catalytic activity for the organosynthesis hydrazination reaction of 4-chloro-3, 5-di-nitro-benzo-triflouride, giving 1-hydroxy-4-nitro-6-trifluoro-methyl benzotriazole, a common antiviral drug for severe acute respiratory syndrome (SARS). SNPs@composite's well-defined pores provide suitable active sites for binding reactants: 4-Cl-3, 5-di-NO2-benzotriflouride, and hydrazine, which react to create 1-hydroxy-4-nitro-6-trifluoromethyl benzotriazole, which diffuses into solution away from the catalyst surface, leaving the catalyst surface unaffected.